Clemens Decristoforo
Medizinische Universität Innsbruck
H-index: 58
Europe-Austria
Top articles of Clemens Decristoforo
Advancing 6-bromo-7-[11C]methylpurine to clinical use: improved regioselective radiosynthesis, non-clinical toxicity data and human dosimetry estimates
EJNMMI Radiopharmacy and Chemistry
2024/4/29
Clemens Decristoforo
H-Index: 34
Position paper to facilitate patient access to radiopharmaceuticals: considerations for a suitable pharmaceutical regulatory framework
EJNMMI Radiopharmacy and Chemistry
2024/1/2
Jan Andersson
H-Index: 11
Clemens Decristoforo
H-Index: 34
The revision of the pharmaceutical legislation—it is time to act for nuclear medicine in Europe
European Journal of Nuclear Medicine and Molecular Imaging
2023/12
Clemens Decristoforo
H-Index: 34
The Regulatory Review of Radiotherapeutics: A European Perspective
2023/11/19
Clemens Decristoforo
H-Index: 34
Proceedings of international symposium of trends in radiopharmaceuticals 2023 (ISTR-2023)
2023/11/10
Clemens Decristoforo
H-Index: 34
Comparison of 99mTc radiolabeled somatostatin antagonist with [68 Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
European Journal of Nuclear Medicine and Molecular Imaging
2023/11
Clemens Decristoforo
H-Index: 34
Highlight selection of radiochemistry and radiopharmacy developments by editorial board
2023/10/27
Automated production of [68Ga] Ga-DOTA-exendin-4 via fractionated radionuclide generator elution on a cassette based synthesis module
Nuclear Medicine and Biology
2023/9/1
Michael Gabriel
H-Index: 12
Clemens Decristoforo
H-Index: 34
Fungal siderophore metabolism with a focus on Aspergillus fumigatus: impact on biotic interactions and potential translational applications
2023/9
Mario Aguiar
H-Index: 7
Clemens Decristoforo
H-Index: 34
The siderophore ferricrocin mediates iron acquisition in Aspergillus fumigatus
Microbiology Spectrum
2023/6/15
Mario Aguiar
H-Index: 7
Clemens Decristoforo
H-Index: 34
Development of the 99mTc-labelled SST2 antagonist TECANT-1 for a first-in-man multicentre clinical study
2023/6/1
Clemens Decristoforo
H-Index: 34
Management of NENs with SSTR2-antagonist: how close are we to a clinical solution? The first results of the TECANT study: Novel 99m-Tc-labelled somatostatin antagonists in the …
Endocrine Abstracts
2023/5/2
Clemens Decristoforo
H-Index: 34
Molecular Design of 68Ga- and 89Zr-Labeled Anticalin Radioligands for PET-Imaging of PSMA-Positive Tumors
Molecular Pharmaceutics
2023/4/17
Improved quality control of [177Lu]Lu-PSMA I&T
EJNMMI Radiopharmacy and Chemistry
2023/3/27
Michael Gabriel
H-Index: 12
Clemens Decristoforo
H-Index: 34
153SM-FAPI-46 RADIOLIGAND THERAPY WITH HIGH-MOLAR ACTIVITY 153SM
2023/3/21
Clemens Decristoforo
H-Index: 34
[111In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final …
European Journal of Nuclear Medicine and Molecular Imaging
2023/2
Clemens Decristoforo
H-Index: 34
MEDICIS-promed: Advances in radioactive ion beams for nuclear medicine
Frontiers in Medicine
2022/10/3
Clemens Decristoforo
H-Index: 34
EANM guideline on quality risk management for radiopharmaceuticals
European Journal of Nuclear Medicine and Molecular Imaging
2022/8
Clemens Decristoforo
H-Index: 34
Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals
2022/7/19
Sangram Nag
H-Index: 12
Clemens Decristoforo
H-Index: 34
Diagnostic guidance for patients with persistent pulmonary abnormalities after COVID-19 infection: the potential benefit of 68Ga-FAPI PET/CT
2022/4/12
Clemens Decristoforo
H-Index: 34
Co-Authors
